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TO THE EDITOR
Nicotinamide (vitamin B3) prevents
photocarcinogenesis in mice (Gensler
et al., 1999) and photoimmunosuppres-
sion in humans (Damian, 2010). Actinic
keratoses (AKs) strongly predict non-
melanoma skin cancer risk (Green and
Battistutta, 1990). These phase II stud-
ies aimed to determine whether oral
nicotinamide, at different doses, reduced
AKs in sun-damaged individuals.
Healthy, immune-competent volun-
teers with X4 palpable AKs (face, scalp
and upper limbs) were recruited from
Royal Prince Alfred Hospital Dermatol-
ogy Clinics, Sydney, Australia. The study
protocols (ACTRN12609000490279;
ACTRN12610000689077; http://www.
anzctr.org.au) adhered to Helsinki
Guidelines and were approved by the
Sydney South West Area Health Service
and University of Sydney ethics com-
mittees. All volunteers provided written
informed consent.
Participants were randomly assigned
(1:1) to take nicotinamide 500 mg
(Nature’s Own, Virginia, Queensland,
Australia) or matched placebo (Austra-
lian Custom Pharmaceuticals, Sydney,
New South Wales, Australia) twice
daily (Study 1) or once daily (Study 2)
for 4 months. The treatment allocation
sequence was determined by a computer-
generated randomization list prepared
using a permuted blocks method (block
size 6) by an investigator (DLD) not
involved in AK assessment. Participants
underwent complete skin examination
before randomization, were encouraged
to use daily sunscreen, and remained
blinded throughout the study.
At baseline, 2 and 4 months, palp-
able AKs were identified visually and
by touch by a blinded observer (DS),
counted and documented on a body
grid chart. At baseline and 2 months,
full blood count, creatinine, and liver
function were assessed.
A target of 36 patients was selected
for Study 1 based on clinical judgement
as this was our first pilot trial of
oral nicotinamide. A conservative
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Table 1. Baseline characteristics and AKs during treatment with nicoti-
namide or placebo
Study 1 (500mg b.d.) Study 2 (500mg o.d.)
Placebo Nicotinamide Placebo Nicotinamide
Patients enrolled 17 18 20 21
Men:women 10.7 15.3 14:6 14:7
Mean age (years; range) 72 (52–90) 71 (59–82) 72 (48–89) 67 (52–80)
Total AKs at baseline
Mean (SD) 31.5 (21.1) 29.3 (23.5) 40.3 (26.5) 30.6 (16.3)
Range (median) 9–92 (23) 6–89 (19) 7–101 (37) 12–73 (27)
Total AKs at 2 months
Mean (SD) 28.2 (20.7) 18.1 (16.8) 35.5 (23.1) 24.3 (14.6)
Range (median) 6–91 (20) 3–65 (11) 5–99 (34) 4–60 (21)
LS mean (95% CI)1 20.9 (18.5-23.5) 13.6 (12.1-15.3) 26.1 (23.2–29.4) 22.1 (19.7–24.8)
Relative reduction (95% CI)1 35% (23–45%) 15% (0–28%)
P-value o0.0001 0.046
Total AKs at 4 months
Mean (SD) 27.1 (19.9) 16.6 (13.9) 34.8 (20.9) 21.6 (14.7)
Range (median) 6–89 (20) 2–54 (10) 5–89 (32) 3–60 (18)
LS mean (95% CI)1 19.9 (16.9–23.4) 12.9 (11.0–15.2) 25.9 (21.9–30.6) 18.3 (15.6–21.6)
Relative reduction (95% CI)1 35% (18–48%) 29% (11–44%)
P-value2 0.0006 0.005
Abbreviations: AKs, actinic keratoses; CI, confidence interval; LS, least squares.
Bold values indicate means and significant P-values.
1Back-transformed estimates from an analysis of covariance performed on the loge(AK count) data at
the time point indicated with treatment group included as a factor and the baseline loge(AK count) as
a covariate. The absolute difference between the groups on loge(AK count) corresponds to the relative
difference between the groups on AK count.
2Very similar P-values were obtained in a sensitivity analysis when the groups were compared on
percentage change from baseline at month 4 in AK count (statistical problems associated with using
percentage change as an endpoint and rationale for statistical adjustment of baseline scores via
analysis of covariance as the optimal analysis approach reviewed in Bonate (2000)).
Abbreviations: AKs, actinic keratoses; BCC, basal cell carcinoma; CI, confidence interval; LS, least-
squares; SCC, squamous cell carcinoma
interpretation of the Study 1 results was
used to inform the assumptions used in
the sample size calculation for Study 2,
where a sample size was selected to
provide X80% power to detect a
standardized effect size of 0.4 at the
two-sided 5% level of significance,
based on an analysis of covariance
model given a correlation of 0.90
between baseline and follow-up assess-
ments (Borm et al., 2007), allowing
for 5% withdrawal.
All randomized patients were eligi-
ble for inclusion in the efficacy analysis
(intention to treat). The primary end-
point obtained for each patient was the
AK count at 4 months. We also noted
all histologically confirmed skin can-
cers during the study. The right-skewed
distribution of the AK data was recti-
fied by applying a loge transforma-
tion (with results back-transformed for
reporting). The relative difference bet-
ween groups on AK count was esti-
mated using an analysis of covariance
adjusting for baseline (Bonate, 2000).
Logistic and Poisson regression was
used to compare treatment groups from
both studies combined on skin cancer
incidence with the number of previous
cancers and study designation fitted as
covariates.
A total of 35 patients were enrolled in
Study 1 (June–October 2009) (Table 1).
One withdrew (nicotinamide) at 2 months
because of invasive squamous cell
carcinoma (SCC), but returned for his
4-month AK count. A total of 41
patients were enrolled in Study 2
(August–November 2010); two with-
drew from treatment (placebo) soon
after their baseline counts because of
nursing-home placement, but agreed to
follow up AK counts. Two nicotinamide
participants withdrew from follow-up
for personal reasons soon after enrol-
ment; their baseline AK counts were
carried forward and included in the
primary analysis (Figures 1 and 2).
AK counts at baseline and follow-
up are shown in the Table 1. A 35%
relative reduction in AK count at
4 months (95% confidence interval
(CI): 18–48%; P¼0.0006) was esti-
mated from Study 1 (with similar results
at 2 months). A 29% relative reduction
in AK count at 4 months (95% CI:
11–44%; P¼0.005) was estimated from
Study 2 (with smaller but significant
differences observed at 2 months).
There was no evidence that the relative
effect of nicotinamide was modified
by baseline AK count (treatment-by-
baseline interaction P-value was non-
significant).
For Studies 1 and 2 combined,
37 patients were randomized to place-
bo and 37 to nicotinamide. Eighty-one
and 79% of placebo and nicotinamide
patients, respectively, had previous,
histologically confirmed skin cancers.
During the 4-month trials, 11 placebo
patients developed 20 new skin cancers
(12 basal cell carcinoma (BCC) and
8 SCC) and 2 nicotinamide patients
developed 4 cancers (2 BCC and
2 SCC). The odds of developing at least
one skin cancer was significantly lower
with nicotinamide (odds ratio¼0.14;
95% CI: 0.03–0.73, P¼0.019) as was
the rate of new skin cancers (relative
rate¼0.24; 95% CI: 0.08–0.71, P¼
0.010) as estimated, respectively, by
Logistic and Poisson regression models
Assessed for eligibility (n =48)
Excluded  (n =13)
♦ Not meeting inclusion criteria (n =7)
♦ Declined to participate (n =6)
♦ Other reasons (n =0)
Analyzed  (n =18)
♦ Excluded from analysis (give reasons) 
   (n =0)
Lost to follow-up (give reasons) (n =0)
Discontinued intervention (give reasons) (n =1)
developed SCC and elected to stop
Allocated to intervention (n =18)
NICOTINAMIDE
♦ Received allocated intervention (n =18)
♦ Did not receive allocated intervention (give
    reasons) (n =0)
Lost to follow-up (give reasons) (n =0)
Discontinued intervention (give reasons) (n =0)
Allocated to intervention (n =17)  PLACEBO
♦ Received allocated intervention (n =17)
♦ Did not receive allocated intervention (give
    reasons) (n =0)
Analyzed  (n =17)
♦ Excluded from analysis (give reasons) 
   (n =0)
Allocation
Follow-up
Randomized (n =35)
Enrollment 
Analysis
Figure 1. CONSORT 2010 flow diagram, study 1: nicotinamide 500mg b.d. versus placebo. SCC, squamous cell carcinoma.
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and adjusting for study and number of
previous skin cancers. The treatment
effect remained significant when anal-
ysis of skin cancer rates was repeated
using a negative binomial model
(P¼ 0.038), although we note the un-
planned nature of this combined anal-
ysis. Compliance, measured by counts of
returned tablets, was 94–98%. One
patient, who was also taking aspirin,
described nausea while taking nicoti-
namide. No other potential side effects
were reported and no clinically sig-
nificant changes in blood profiles were
observed.
The mechanisms by which nicotin-
amide might prevent skin cancer or
reduce progression of subclinical lesions
are unclear. Nicotinamide is a substrate
and inhibitor of the nuclear enzyme
poly-ADP-ribose polymerase, which is
centrally involved in DNA repair (Virag
and Szabo, 2002). As a precursor of
nicotinamide adenine dinucleotide,
nicotinamide prevents the decline in
cellular energy observed after UV expo-
sure (Park et al., 2010), and could
therefore maintain efficient DNA repair.
Immunosuppression has a key role in the
malignant transformation of AKs (Frost
and Green, 1994), and nicotinamide is
highly immune protective in humans
(Damian et al., 2008). Hence, nicotin-
amide protection from photoimmuno-
suppression (Yiasemides et al., 2009)
may be a key mediator of the reduction
in AKs observed here.
Spontaneous fluctuation in AK
counts has been previously reported
(Criscione et al., 2009; Moloney et al.,
2010), consistent with the 13–15%
reduction from baseline observed in
our placebo groups. Our randomized,
double-blinded design enabled detec-
tion of AK reductions with nicotin-
amide relative to any background
variations in AKs due to seasonal and
behavioral fluctuations in UV doses.
Nicotinamide is well tolerated and
costs $5–$10 per month at the doses
used here. The results of these phase II
studies suggest nicotinamide is effective
in reducing AKs and shows promise for
skin cancer chemoprevention. A longer
phase III trial in a larger cohort, with
new skin cancers as the primary end-
point, is now warranted.
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Assessed for eligibility (n =53)
Excluded  (n =12)
♦ Not meeting inclusion criteria (n =2)
♦ Declined to participate (n =10)
♦ Other reasons (n =0)
Analyzed (n =21)
♦ Excluded from analysis (give reasons) 
   (n =0)
Lost to follow-up (give reasons) (n =2)
Discontinued intervention (give reasons) (n =2)
One elected to stop; one traveled overseas
Allocated to intervention (n =21)
NICOTINAMIDE 
♦ Received allocated intervention (n =21)
♦ Did not receive allocated intervention (give
   reasons) (n =0)
Lost to follow-up (give reasons) (n = 0)
Discontinued intervention (give reasons) (n =2)
Two elderly patients had nursing-home
placement (general frailty) and elected to 
cease tablets but agreed to continue follow-up
Allocated to intervention (n = 20) PLACEBO 
♦ Received allocated intervention (n = 20)
♦ Did not receive allocated intervention (give
   reasons) (n =0)
Analyzed (n =20)
♦ Excluded from analysis (give reasons)
   (n =0)
Allocation
Analysis
Follow-up
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Figure 2. CONSORT 2010 flow diagram, study 2: nicotinamide 500mg daily versus placebo.
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Interpretation of Skindex-29 Scores: Response to
Sampogna and Abeni
Journal of Investigative Dermatology (2012) 132, 1500–1501; doi:10.1038/jid.2012.5; published online 16 February 2012
TO THE EDITOR
Until recently, little was known about
the interpretability of scores of the
Skindex-29, a well-established, derma-
tology-specific health-related quality of
life (HRQoL) instrument (Chren et al.,
1997a, b). Nijsten et al. (2009) and
Prinsen et al. (2010, 2011) were the
first to identify the clinical meaningful-
ness of Skindex-29 scores by estimating
a categorization of Skindex-29 scores,
denoting mildly, moderately, and (very)
severely impaired HRQoL (Nijsten
et al., 2009; Prinsen et al., 2010, 2011).
In their thoughtful commentary in
the Journal of Investigative Dermatol-
ogy, 131, (9) September 2011, Sampog-
na and Abeni persuasively showed how
different methods, a distribution-based
and an anchor-based method, respec-
tively, result in different categoriza-
tions of scores (Sampogna and Abeni,
2011). They applied the distribution-
based ranges of scores found by Nijsten
et al. and the anchor-based cutoff
scores found by Prinsen et al. to an
Italian sample of inpatients diagnosed
with psoriasis, and to another Italian
sample of dermatological outpatients.
By means of this comparison, differ-
ences between the two categorizations
were shown; in general, the ranges of
scores presented by Nijsten et al. were
lower than the cutoff scores presented
by Prinsen et al. Sampogna and Abeni
also explored the clinical implications
of these differences, for instance the
consequence of using different cate-
gories in determining patient’s eligibil-
ity for systemic treatment.
Unfortunately, a misinterpretation
leading to an incorrect categorization
Table 1. An overview of the Skindex-291 cutoff scores derived by an anchor-based method (Prinsen et al.)2 and the
ranges of scores derived by a distribution-based method (Nijsten et al.)3
Symptoms Emotions Functioning Overall
Categorization Prinsen et al. Nijsten et al. Prinsen et al. Nijsten et al. Prinsen et al. Nijsten et al. Prinsen et al. Nijsten et al.
Very little — o3 — o5 — o3 — o5
Mild X39 4–10 X24 6–24 X21 4–10 X25 6–17
Moderate X42 11–25 X35 25–49 X32 11–32 X32 18–36
Severe X52 26–49 X39 450 X37 433 X44 437
Very severe — 450 — — — — — —
1The domain scores and the overall score are expressed on a 100-point scale, with higher scores indicating a lower level of quality of life.
2Skindex-29 cutoff scores are derived from the original articles (Prinsen et al., 2010, 2011).
3Categorization of Skindex-29 scores are derived from the original article (Nijsten et al., 2009).
Abbreviations: HRQoL, health-related quality of life
1500 Journal of Investigative Dermatology (2012), Volume 132
CAC Prinsen et al.
Interpretation of Skindex-29 Scores
